Filtered By:
Specialty: Drugs & Pharmacology
Condition: Pain
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 111 results found since Jan 2013.
Dipyrone comedication in aspirin treated stroke patients impairs outcome.
CONCLUSIONS: Dipyrone comedication in patients with stroke impairs pharmacodynamic response to aspirin. This is associated with worse clinical outcome. Therefore dipyrone should be used with caution in aspirin treated stroke patients.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/show/NCT02148939; Identifier: NCT02148939.
PMID: 27301652 [PubMed - as supplied by publisher]
Source: Vascular Pharmacology - June 10, 2016 Category: Drugs & Pharmacology Authors: Dannenberg L, Erschoff V, Bönner F, Gliem M, Jander S, Levkau B, Kelm M, Hohlfeld T, Zeus T, Polzin A Tags: Vascul Pharmacol Source Type: research
Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis
Conclusions: The limited number of the included studies and their heterogeneity in terms of study design do not support the efficacy of opioids in post-stroke pain and in pain-related outcomes. Large double-blind randomized clinical trials with objective assessment of pain and related symptoms are needed to further investigate this topic.
Source: Frontiers in Pharmacology - November 27, 2020 Category: Drugs & Pharmacology Source Type: research
Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis
ConclusionsClinicians should look for any evidence of central neuropathic pain for at least 12 months after stroke. Both pharmacological and non-pharmacological interventions can be used for the management of CPSP. Lamotrigine has the strongest evidence (Level II of evidence, derived from small randomized controlled trials) for being effective in the management of CPSP. Future research sho uld focus on well-designed trials of pharmacological and non-pharmacological interventions aiming to relief CPSP, which is a very common but often neglected pain syndrome.
Source: Advances in Therapy - May 22, 2020 Category: Drugs & Pharmacology Source Type: research
Observation of clinical efficacy of rt-PA intravenous thrombolytic treatment for patients combined with grade 0-1 diabetic foot by Wagner classification and acute ischemic stroke.
CONCLUSIONS: rt-PA can reduce the level serum fibrinogen, promotes local microcirculation and nutrition metabolism of diabetic foot, and improve the clinical prognosis of patients with diabetic foot, but will not increase the incidence of adverse events at the same time.
PMID: 28051251 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 6, 2017 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation.
Conclusions: Perispinal etanercept can provide significant and ongoing benefits for the chronic post-stroke management of pain and greater shoulder flexion by the paretic arm. Effects are rapid and highly significant, supporting direct action on brain function.Trial registration: ACTRN12615001377527 and Universal Trial Number U1111-1174-3242.
PMID: 31899977 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - January 6, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Bilateral Motor Cortex tDCS Effects on Post-Stroke Pain and Spasticity: A Three Cases Study
Stroke patients frequently suffer from chronic limb pain, but well-suited treatment approaches have been not established so far. Transcranial direct current stimulation (tDCS) is a safe and non-invasive brain stimulation technique that alters cortical excitability, and it has been shown that motor cortex tDCS can reduce pain. Some data also suggest that spasticity may be improved by tDCS in post-stroke patients. Moreover, multiple sessions of tDCS have shown to induce neuroplastic changes with lasting beneficial effects in different neurological conditions. The aim of this pilot study was to explore the effect of multiple ...
Source: Frontiers in Pharmacology - April 21, 2021 Category: Drugs & Pharmacology Source Type: research
Neither nefopam nor acetaminophen can be used as post ‐operative analgesics in a rat model of ischemic stroke
This article is protected by copyright. All rights reserved.
Source: Fundamental and Clinical Pharmacology - September 30, 2016 Category: Drugs & Pharmacology Authors: Maud P étrault, Sophie Gautier, Vincent Bérézowski, Thavarak Ouk, Michèle Bastide, Olivier Pétrault, Régis Bordet Tags: Original Article Source Type: research
NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned
ABSTRACT
The selective AMPA (α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid) receptor antagonist, NS1209 (also known as SPD 502) has been explored in several research and development campaigns since its selection as a lead drug candidate in the early 1990s by the Danish biotechnology company, NeuroSearch. The compound was successively tested in animal models of stroke, neuropathic pain and epilepsy. The preclinical data to support development for the treatment of stroke were incomplete, as the compound was administered after the stroke episode, and did not protect subcortical areas of the brain....
Source: Drug Development Research - January 31, 2017 Category: Drugs & Pharmacology Authors: Jan M. Keppel Hesselink Tags: Miscellaneous Source Type: research
IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study
ConclusionsRepeated injections of incobotulinumtoxinA for the treatment of post-stroke upper-limb spasticity led to significant improvements in muscle tone and investigator ’s global impression of change. Treatment was well tolerated, with no serious treatment-related AEs.FundingMerz Pharmaceuticals GmbH.
Source: Advances in Therapy - November 27, 2018 Category: Drugs & Pharmacology Source Type: research
Involvement of descending pain control system regulated by orexin receptor signaling in the induction of central post-stroke pain in mice.
In this study, we tested the role of orexin-A in CPSP induction in mice. Male ddY mice were subjected to 30 min of bilateral carotid artery occlusion (BCAO). CPSP was assessed by von Frey test. Colocalization of orexin 1 receptor (OX1R) with various neuron markers were determined by double-immunofluorescence. The hindpaw withdrawal responses to mechanical stimuli were significantly increased 3 days post-BCAO compared with those of sham groups. ICV injection of orexin-A dose-dependently suppressed BCAO-induced mechanical allodynia. These effects were inhibited by pre-treatment with SB334867 (an OX1R antagonist; ICV inject...
Source: European Journal of Pharmacology - February 17, 2020 Category: Drugs & Pharmacology Authors: Matsuura W, Nakamoto K, Tokuyama S Tags: Eur J Pharmacol Source Type: research
Jiedu Tongluo Granules Ameliorates Post-stroke Depression Rat Model via Regulating NMDAR/BDNF Signaling Pathway
Post-stroke depression (PSD) is one of the most common stroke complications, which seriously affects stroke’s therapeutic effect and brings great pain for patients. The pathological mechanism of PSD has not been revealed. Jiedu Tongluo granules (JDTLG) is an effective traditional Chinese medicine for PSD treatment which is widely used in clinical treatment. JDTLG has a significant therapeutic effect against PSD, but the mechanism is still unclear. The PSD rat model was established by carotid artery embolization combined with chronic sleep deprivation followed by treating with JDTLG. Neurobehavioral and neurofunctional ex...
Source: Frontiers in Pharmacology - May 20, 2021 Category: Drugs & Pharmacology Source Type: research
Although pharmacological treatment may have beneficial effects in central post-stroke pain, it does not abolish the symptoms
Abstract
The management of central post-stroke pain is challenging. Amitriptyline is considered the first-line pharmacological choice, with lamotrigine, gabapentin and pregabalin used as alternative therapies. If the therapeutic response with monotherapy is insufficient, combination therapy (e.g. an adrenergic antidepressant plus an antiepileptic) may be considered.
Source: Drugs and Therapy Perspectives - February 4, 2015 Category: Drugs & Pharmacology Source Type: research
Chronic cerebral aspects of long COVID, post ‐stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic
This article is about how the neurological aspects of long COVID (fatigue, neurogenic pain, loss of ability to taste or smell), can be best understood, and treated. For this purpose, the literature on TNF and brain function, both physiological and disease-associated, and how this is being applied to various long-term neurodegenerative conditions, is discussed. AbstractThe chronic neurological aspects of traumatic brain injury, post-stroke syndromes, long COVID-19, persistent Lyme disease, and influenza encephalopathy having close pathophysiological parallels that warrant being investigated in an integrated manner. A mechan...
Source: Pharmacology Research and Perspectives - February 17, 2022 Category: Drugs & Pharmacology Authors: Ian Albert Clark Tags: REVIEW ARTICLE Source Type: research
Nicotine suppresses central post-stroke pain via facilitation of descending noradrenergic neuron through activation of orexinergic neuron
In this study, we evaluated whether nicotine could suppress BCAO-induced mechanical allodynia through the activation of orexinergic neurons. Mice were subjected to BCAO for 30 min. Mechanical hypersensitivity was assessed by the von Frey test. BCAO mice showed hypersensitivity to mechanical stimuli three days after BCAO surgery. The intracerebroventricular injection of nicotine suppressed BCAO-induced mechanical hypersensitivity in a dose-dependent manner. These effects were inhibited by α7 or α4β2-nicotinic receptor antagonists. After nicotine injection, the level of c-fos, a neuronal activity marker, increased in the ...
Source: European Journal of Pharmacology - January 27, 2023 Category: Drugs & Pharmacology Authors: Kazuo Nakamoto Wataru Matsuura Shogo Tokuyama Source Type: research
